The short version of Nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
The R1 plasmid is a plasmid that was first isolated from Salmonella paratyphi bacteria in 1963. It is a short plasmid, composed of 97,566 nucleotides and 120 genes, that belongs to the IncFII plasmid group. There are about one to two copies of the R1 plasmid per chromosome. The R1 plasmid imparts multi-drug antibiotic resistance to its host bacteria. The "R" in "R1" stands for "resistance", and the R1 plasmid contains resistance factors, or R factors, giving it the power to resist certain antibiotics. It's known as a "low copy" plasmid, meaning that it exists in relatively few copies in any given bacteria. This characteristic allows the R1 plasmid to have an efficient plasmid stabilization system, that aids in stabilizing medium copy number plasmids. R1 must rely on a "Type II" segregation system. This plasmid system ensures that at least one copy is contained in each daughter cell after cell division.
The surgeon designs the nasolabial flap and sets its central axis at a 45-degree angle from the (long) axis of the nasal dorsum. The shape of the skin flap is cut from the wound template fabricated by the surgeon. An incision is made to the flap (without an anaesthetic injection of epinephrine), which then is elevated and oriented, in an inferior-to-superior direction, between the subcutaneous fat and the muscle fascia. The cutting continues until the skin flap can be freely transposed upon the nasal defect. A Burrow's triangle is excised from the skin between the medial border of the flap and the nasal dorsum; the triangle can be cut either before or after the elevation of the nasolabial. The flap then is bent back (reflected), and can be thinned (cut) under loupe magnification; however, a nasolabial flap cannot be thinned as easily as an axial skin-flap. After the nasolabial flap has been emplaced, the flap donor-site wound is sutured closed. For a wound of the lateral nasal wall that is less than 15 mm wide, the flap donor-site can be closed primarily, with sutures. For a wound wider than 15 mm—especially a wound that comprehends the alar lobule and the lateral wall of the nose—primary closure is not indicated, because such a wound closure imposes excessive stresses upon the skin flap, thereby risking either blanching (whitening) or distortion, or both. Such risks are avoided by advancing (moving) the skin of the cheek towards the nasofacial junction, where it is sutured to the deep tissues.
The chain attempted to enter large European markets thanks to joints with KFC. In Germany the first non-military A&W restaurant opened in Garbsen near Hanover on May 27, 2003 followed by a second in Cologne in July. A third in Berlin was scheduled for early September. A&W opened its first outlet in Bangladesh on December 15, 2004. The outlet reportedly closed in 2024. Indonesia hit a record milestone, as the hundredth restaurant opened in Bintaro Utama on October 20, 2004. By the end of 2004, all A&W restaurants in the Philippines were closed. Most A&W stores that opened in the U.S. during Yum!'s ownership were co-branded with another of Yum!'s chains—Long John Silver's, Pizza Hut, Taco Bell, or KFC. In 2009, its operations in Southeast Asia were in a mixed situation. Operations in Indonesia and Bangladesh were thriving, while the restaurants in Thailand and Malaysia were facing uncertainties. The Malaysian franchisee KUB planned to increase the number of restaurants to 60, up from 37 in 2012, despite net losses of $1.5 million. For its 90th anniversary, A&W announced an expansion plan to open fifteen new drive-ins in a concept the chain dubbed "Three-D Drive In: Drive-In, Drive-Through, Dine-In". Growth was more expeted in the states of Wisconsin, Michigan and Oregon, where some of these Three-D units were set up in 2008.
A majority of Generation Z disagreed that it was necessary to raise children in a religious household, and only a minority deemed religion to be an important part of their lives. On the other hand, the Pew Research Center found the gap in spirituality among the old and the young to be more modest. In a 2016 poll, Barna found that Millennials and Generation Z were equally likely to require factual evidence before believing in something and to consider the Bible to be at odds with science. The same Barna survey revealed that the percentage of atheists and agnostics was 21% among Generation Z, higher than all previous cohorts. Moreover, whereas in the past, women were broadly more religious than men, during the 2020s, young women secularizing faster than young men, and have become just about as religious as men. Youths who still hold private religious beliefs are also less likely to go to church. When asked what their biggest barriers to faith were, irreligious members of Generation Z pointed to what they perceived as internal contradictions of the religion and its believers. Many also took issue with religious leaders' positions on certain social and political topics, such as abortion, homosexuality, and sex-abuse scandals of the Church. Young women in particular disapproved of the Church's emphasis on traditional gender roles, especially the subservience of women before men, and the culture of purity, such as the insistence that women must dress "modestly" because they were responsible for the thoughts of men.
by correcting the error – entering a new value for example or when the datapoint is updated by marking the variable as correct – some EDC systems required additional response or you can raise a further query if you are not satisfied with the response
Sources: en.wikipedia.org
=== Cellular effects of C-peptide === C-peptide has been shown to bind to the surface of a number of cell types such as neuronal, endothelial, fibroblast and renal tubular, at nanomolar concentrations to a receptor that is likely G-protein-coupled. The signal activates Ca2+-dependent intracellular signaling pathways such as MAPK, PLCγ, and PKC, leading to upregulation of a range of transcription factors as well as eNOS and Na+K+ATPase activities. The latter two enzymes are known to have reduced activities in patients with type I diabetes and have been implicated in the development of long-term complications of type I diabetes such as peripheral and autonomic neuropathy. In vivo studies in animal models of type 1 diabetes have established that C-peptide administration results in significant improvements in nerve and kidney function. Thus, in animals with early signs of diabetes-induced neuropathy, C peptide treatment in replacement dosage results in improved peripheral nerve function, as evidenced by increased nerve conduction velocity, increased nerve Na+,K+ ATPase activity, and significant amelioration of nerve structural changes. Likewise, C-peptide administration in animals that had C-peptide deficiency (type 1 model) with nephropathy improves renal function and structure; it decreases urinary albumin excretion and prevents or decreases diabetes-induced glomerular changes secondary to mesangial matrix expansion. C-peptide also has been reported to have anti-inflammatory effects as well as aid repair of smooth muscle cells.
Leprecan (also called prolyl 3-hydroxylase 1) is an enzyme which in humans is encoded by the gene P3H1. Certain mutations in the gene have been associated with osteogenesis imperfecta type VIII. Leprecan is part of a superfamily of 2OG-Fe(II) dioxygenase, along with DNA repair protein AlkB, and disease resistant EGL-9. The enzyme was found to be a type of hydroxylases used in the substrate formation of protein glycosylation.
==== Platelet-type ==== Platelet-type VWD (also known as pseudo-VWD) is an autosomal dominant genetic defect of the platelets. The VWF is qualitatively normal and genetic testing of the von Willebrand gene and VWF protein reveals no mutational alteration. The defect lies in the qualitatively altered GPIb receptor on the platelet membrane which increases its affinity to bind to the VWF. Large platelet aggregates and high molecular weight VWF multimers are removed from the circulation resulting in thrombocytopenia and diminished or absent large VWF multimers. The ristocetin cofactor activity and loss of large VWF multimers are similar to VWD type 2B.
== Early life and education == Born in 1953 and raised in Dearborn, Michigan, Tippett is an alumnus of Kalamazoo College and holds a Ph.D. and M.D. from Case Western Reserve University School of Medicine. He studied at the Rockefeller University in New York under Nobel Prize winner Robert Bruce Merrifield, directing his doctoral research efforts toward the metabolic indicators of peptide synthesis. He completed his internship and residency in Internal Medicine at Cleveland Metropolitan General Hospital, and spent 1975-1985 engaged in biochemical research.
==== Phase I–II ==== A phase I safety trial began on 18 June 2020. On 4 September 2020, data on 76 participants in a phase I–II trial were published, indicating preliminary evidence of safety and an immune response. The results were challenged by international vaccine scientists as being incomplete, suspicious, and unreliable when identical data were reported for many of the trial participants, but the authors responded that there was a small sample size of nine, and the measured results of titration could only take discrete values (800, 1600, 3200, 6400). Coupled with the observation that values tended to reach a plateau after three to four weeks, they contend that it is not unlikely that several participants would show identical results for days 21 to 28.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.